How Are Proto-Oncogenes Targeted in Cancer Therapy?
Targeting oncogenes and their protein products has become a cornerstone of targeted cancer therapies. For instance, the drug Trastuzumab targets the HER2 protein in HER2-positive breast cancer. Imatinib is used to treat CML by inhibiting the BCR-ABL fusion protein. These targeted therapies are designed to specifically inhibit the activity of the oncogenic proteins, thereby reducing tumor growth and proliferation.
